

AARON T. WILD, M.D.

ADDRESS:

303 East 60th Street
Apartment 8A
New York, NY 10022
(860) 287-7935
wilda@mskcc.org

GRADUATE MEDICAL EDUCATION:

07/2018 – 06/2019 Chief Resident – Memorial Sloan Kettering Cancer Center, New York, NY
07/2015 – 06/2019 Radiation Oncology Residency – Memorial Sloan Kettering Cancer Center, New York, NY
06/2014 – 06/2015 Transitional Year Internship – Memorial Sloan Kettering Cancer Center, New York, NY

PREDOCTORAL EDUCATION:

08/2008 – 05/2014 M.D., May 2014 – Johns Hopkins University School of Medicine, Baltimore, MD
08/2004 – 05/2008 B.A., Molecular Biophysics & Biochemistry, May 2008 – Yale University, New Haven, CT
08/2000 – 06/2004 Diploma, May 2004 – Waterford High School, Waterford, CT

HONORS AND AWARDS:

2018 ASTRO 2018 Annual Meeting Resident Clinical/Basic Science Award – Highest-scoring Abstract in the Radiation and Cancer Biology Category
2014 Alpha Omega Alpha (ΑΩΑ) Honor Medical Society (Member Number: 0178647)
2013 2nd Place Presentation at the Johns Hopkins Dept. of Radiation Oncology Research Retreat
2012 Radiological Society of North America (RSNA) Research Medical Student Grant Recipient
2012 American Medical Association (AMA) Foundation Research Seed Grant Recipient
2012 The Gordon and Marilyn Macklin Foundation Fellowship
2012 1st Place Presentation in Research Division at the American College of Physicians (ACP) Steps to Success Meeting
2011 Johns Hopkins University Dean's Predoctoral Year of Research Fellowship
2009 Johns Hopkins University Dean's Summer Research Fellowship
2008 Magna cum laude
2008 Honors in Molecular Biophysics & Biochemistry
2008 Phi Beta Kappa (ΦBK) Society (Member Number: 1323818)
2007 Yale University International Bulldogs Summer Research Fellowship
2005 Yale University Perspectives on Science Grant Recipient
2004 Valedictorian

RESEARCH EXPERIENCE:

2017 – present Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center
PI: Timothy Chan, M.D., Ph.D.
Concentration: Translational laboratory research focusing on exploitation of 2-hydroxyglutarate-mediated deficiency in homologous recombination with PARP inhibition to achieve radiosensitization in *IDH*-mutant glioma and intrahepatic cholangiocarcinoma

2017 – present Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center
PI: Yoshiya (Josh) Yamada, M.D., F.R.C.P.C.
Concentration: Prospective clinical research focusing on use of single-fraction stereotactic radiosurgery to treat refractory chronic back pain through spinal nerve root ablation

2011 – 2013 Department of Radiation Oncology, Johns Hopkins University School of Medicine
PI: Joseph Herman, M.D., M.Sc., M.S.H.C.M., F.A.C.R.
Concentration: Clinical research focusing on gastrointestinal malignancies

- 2011 – 2013 Department of Radiation Oncology, Johns Hopkins University School of Medicine
 PI: Phuoc Tran, M.D., Ph.D.
 Concentration: Translational laboratory research focusing on hepatocellular carcinoma and prostate cancer, including projects examining radiosensitivity, a prognostic gene signature, acquired resistance, and epithelial-mesenchymal transition
- 6/2007 – 8/2007 Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM), Department of Biotechnology, Nuevo León, Mexico
 PI: Marco Antonio Rito Palomares, Ph.D.
 Concentration: Basic/translational laboratory research focusing on screening of compounds derived from unique local flora for anticarcinogenic activity
- 2006 – 2007 Yale University, Department of Ecology & Evolutionary Biology
 PI: Leo W. Buss, Ph.D.
 Concentration: Basic laboratory research focusing on characterization of the cellular biology underlying histocompatibility and allorecognition in the marine colonial hydroid *Hydractinia symbiolongicarpus* using transmission electron microscopy
- 2005 – 2007 Yale University, Department of Molecular Biophysics & Biochemistry
 PI: Nigel D. F. Grindley, Ph.D.
 Concentration: Basic laboratory research focusing on characterization of the biochemical properties of the active site of DNA polymerase I in *Escherichia coli* using site-directed mutagenesis and kinetic studies of mutant polymerase fidelity

LICENSURES AND CERTIFICATIONS:

- 2015 – present New York State Medical License No. 281089
 2013 – present National Provider Identification No. 1124397328
 2010 – 2014 National Board of Medical Examiners Step I, Step II CS, Step II CK, and Step III

PROFESSIONAL AFFILIATIONS:

- 2012 – present Radiological Society of North America (RSNA)
 2015 – present American College of Radiology (ACR)
 2015 – present New York Roentgen Society (NYRS)
 2016 – present American Society for Radiation Oncology (ASTRO)
 2016 – present American College of Radiation Oncology (ACRO)

LEADERSHIP AND COMMITTEE POSITIONS:

- 2018 – present Radiation Oncology Residency, Memorial Sloan Kettering Cancer Center—**Chief Resident**
 2018 – present Resident Education Committee, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center—**Member**
 2018 – present Quality Assurance Committee, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center—**ad hoc Member**
 2011 – 2013 Radiation Oncology Interest Group (ROIG), Johns Hopkins University—**Founder/co-chair**
 2010 – 2011 Surgery Interest Group (SIG), Johns Hopkins University—**Co-chair**
 2010 – 2011 Surgical Skills Society (SSS), Johns Hopkins University—**Founder/co-chair**
 2009 – 2010 Orthopedic Surgery Interest Group (OSIG), Johns Hopkins University—**Co-chair**

EDITORIAL POSITIONS:

- 2018 – 2019 Reviewer for American Medical Informatics Association (AMIA) Annual Symposium
 2014 – 2015 Reviewer for American Medical Association (AMA) Foundation Research Seed Grant

TEACHING POSITIONS:

- 2017 – present Lecturer at Memorial Sloan Kettering Cancer Center School of Radiation Therapy, 1275 York Avenue, New York, NY 10022

MANUSCRIPTS IN PRESS:

1. Wang Y, Yang J, **Wild A**, Wu W, Shah R, Danussi C, Riggins G, Kannan K, Sulman E, Chan T, Huse J. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. *Nature Communications*. 2019; in press (manuscript #NCOMMS-18-17273B).

PUBLISHED MANUSCRIPTS:

[First Author]

1. **Wild AT**, Yamada Y. Treatment options in oligometastatic disease: stereotactic body radiation therapy—focus on colorectal cancer. *Visc Med*. 2017; 33(1):54-61. PMID: 28612018.
2. **Wild AT**, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2016;94(3):571-9. PMID: 26867885.
3. **Wild AT**, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, Laheru DA, Zheng L, De Jesus-Acosta A, Ellsworth SG, Hacker-Prietz A, Voong KR, Tran PT, Hruban RH, Pawlik TM, Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenocarcinoma of the pancreas. *J Gastrointest Oncol*. 2015;6(2):115-25. PMID: 25830031.
4. **Wild AT**, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: Experience from two institutions. *J Gastrointest Oncol*. 2013;4(4):343-51. PMID: 24294505.
5. **Wild AT**, Gandhi N, Chettiar ST, Aziz KA, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. *PLoS ONE*. 2013;8(6):e65726. PMID: 23762417.
6. **Wild AT**, Ye X, Ellsworth S, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. *Am J Clin Oncol*. 2015;38(3):259-65. PMID: 23648440.
7. **Wild AT**, Fan KY, Herman JM. Management of pancreatic cancer. *Curr Probl Cancer*. 2013;37(5):259-61. PMID: 24331179.
8. Kumar R, **Wild AT [co-first author]**, Ziegler MA, Smith K, Kang J, Hooker TK, Dah SD, Tran PT, Zeng J, Pawlik TM, Tryggestad E, Ford E, Herman JM. Stereotactic body radiation therapy planning with duodenal sparing using volumetric modulated arc therapy versus intensity modulated radiation therapy for locally advanced pancreatic cancer: A dosimetric analysis. *Med Dosim*. 2013;38(3):243-50. PMID: 23540490.
9. Herman JM, **Wild AT [co-first author]**, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. A randomized phase III multi-institutional study of TNFerade™ biologic with 5-fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results. *J Clin Oncol*. 2013;31(7):886-94. PMID: 23341531.

10. Gandhi N, **Wild AT [co-first author]**, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT. Novel Hsp90 inhibitor NVP-AUY022 radiosensitizes prostate cancer cells. *Cancer Biol Ther*. 2013; 14(4): 347-56. PMID: 23358469.
11. Smith JA, **Wild AT [co-first author]**, Singhi A, Raman SP, Qiu H, Kumar R, Hacker-Prietz A, Hruban RH, Kamel IR, Efron J, Wick EC, Azad NS, Diaz LA, Le Y, Armour EP, Gearhart SL, Herman JM. Clinicopathologic comparison of high-dose-rate endorectal brachytherapy versus conventional chemoradiotherapy in the neoadjuvant setting for resectable stage II and III low rectal cancer. *Int J Surg Oncol*. 2012; 406568. PMID: 22830003.
12. **Wild AT**, Begly JP, Garzon-Muvdi J, Desai P, McFarland EG. First-rib stress fracture in a high-school lacrosse player: a case report and short clinical review. *Sports Health*. 2011;3(6):547-549. PMID: 23016057.
13. **Wild AT**, Sponseller PD, Stec AA, Gearhart JP. The role of osteotomy in surgical repair of bladder exstrophy. *Semin Pediatr Surg*. 2011;20(2):71-78. PMID: 21453849.

[Non-first Author]

14. Fan KY, **Wild AT**, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. *Contemp Clin Trials*. 2016 Sep;50:143-9. PMID: 27520932
15. Grossman SA, Ellsworth S, Campian J, **Wild AT**, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X. Survival following treatment with radiation and chemotherapy in patients with solid tumors and severe treatment-related lymphopenia. *J Natl Compr Canc Netw*. 2015;13(10):1225-31. PMID: 26483062.
16. Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, **Wild AT**, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: Implications for surgical management. *Ann Surg*. 2016;263(1):153-61. PMID: 26020105.
17. Elnahal SM, Moningi S, **Wild AT**, Dholakia AS, Hodgkin M, Fan KY, Huang P, Pronovost P, Pawlik TM, Herman JM. Improving safe patient throughput in a multidisciplinary oncology clinic. *Physician Leadersh*. 2015;2(2):56-60, 62, 64-5. PMID: 26211213.
18. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith MB, Pawlik TM, Pai J, O'Reilly E, Fisher G, **Wild AT**, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer*. 2015;121(7):1128-37. PMID: 25538019.
19. Walker AJ, Alcorn SR, Narang AK, Nugent KM, **Wild AT**, Herman JM, Tran PT. Radiosensitizers in pancreatic cancer—preclinical and clinical exploits with molecularly targeted agents. *Curr Probl Cancer*. 2013;37(5):301-12. PMID: 24331186.
20. Fan KY, Dholakia AS, **Wild AT**, Su Z, Hacker-Prietz A, Kumar R, Hodgkin M, Hsu CC, Le DT, De Jesus-Acosta A, Diaz Jr LA, Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM. Baseline hemoglobin-A1c impacts clinical outcomes in Patients with pancreatic cancer. *J Natl Compr Canc Netw*. 2014;12(1):50-57. PMID: 24453292.

21. Dholakia AS, Hacker-Prietz A, **Wild AT**, Raman SP, Wood LD, Huang P, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, Schulick RD, Edil BH, Yovino SG, Pawlik TM, Iacobuzio-Donahue AC, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer is not dependent on improved tumor-vessel relationships. *J Radiat Oncol*. 2013;2(4):413-425. PMID: 25755849.
22. Herman JM, Fan KY, **Wild AT**, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy following resection for pancreatic adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 2013;87(3):458-9. PMID: 24074918.
23. Alcorn S, Walker AJ, Gandhi N, Narang A, **Wild AT**, Hales RK, Herman JM, Song DY, DeWeese TL, Antonarakis ES, Tran PT. Molecularly targeted agents as radiosensitizers in cancer therapy—Focus on prostate cancer. *Int J Mol Sci*. 2013;14(7):14800-32. PMID: 23863691.
24. Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, **Wild AT**, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung C, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT. The Twist box is required for Twist1-induced prostate cancer metastasis. *Mol Cancer Res*. 2013;11(11):1387-400. PMID: 23982216.
25. Herman JM, Fan KY, **Wild AT**, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Phase 2 Study of Erlotinib Combined with Adjuvant Chemoradiation and Chemotherapy in Patients with Resectable Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2013;86(4):678-85. PMID: 23773391.
26. Jabbour SK, Patel S, Herman JM, **Wild A**, Nagda SN, Altoos T, Tunceroglu A, Azad, N, Gearheart S, Moss RA, Poplin E, Levinson LL, Chandra RA, Moore DF, Chen C, Haffty BG, Tuli R. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. *Int J Surg Oncol*. 2012; 891067. PMID: 22934164.
27. Khashab MA, Kim KJ, Tryggestad EJ, **Wild AT**, Roland T, Ziegler MA, Shin EJ, Sharaiha RZ, Singh VK, Lennon AM, Canto MI, Herman JM. Comparative analysis of traditional and visicoil fiducials implanted during endoscopic ultrasound for pancreatic cancer patients receiving stereotactic body radiation therapy. *Gastrointest Endosc*. 2012;76(5):962-71. PMID: 23078921.
28. Qiu H, **Wild AT**, Wang H, Fishman EK, Hruban RH, Laheru DA, Kumar R, Hacker-Prietz A, Tuli R, Tryggestad E, Schulick RD, Cameron JL, Edil BH, Pawlik TM, Wolfgang CL, Herman JM. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: Implications for radiation therapy planning. *Radiother Oncol*. 2012;104(2):167-72. PMID: 22883106.
29. Begly JP, **Wild AT**, Garzon-Muvdi J, Carrino JA, McFarland EG. Sports Health orthopaedic magnetic resonance imaging challenge: shoulder pain from a fall while surfing. *Sports Health*. 2012;4(3):261-3. PMID: 23016097.
30. Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, **Wild AT**, Kumar R, Herman JM, Song D, Dewese TL. Tissue biomarkers for prostate cancer radiation therapy. *Curr Mol Med*. 2012;12(6):772-87. PMID: 22292443.

SUBMITTED MANUSCRIPTS:

1. Iocolano M, **Wild AT**, Hannum M, Zhang Z, Simone II CB, Gelblum D, Wu AJ, Rimmer A, Shepherd A. Patterns of care and outcomes of hypofractionated radiation therapy vs. conventionally fractionated radiation therapy in patients with stage III non-small cell lung cancer undergoing definitive radiation therapy alone. *Clinical Lung Cancer*. Submitted 12/24/2018.

ORAL PRESENTATIONS AT NATIONAL CONFERENCES:

1. **Wild AT**, Wang Y, Wu W, Haddock SL, Chan TA. Exploitation of 2-hydroxyglutarate-mediated deficiency in homologous recombination with PARP inhibition to achieve radiosensitization in IDH-mutant tumors. Oral presentation at the 2018 ASTRO Annual Meeting, San Antonio, TX, October 21-24, 2018.
2. Leeman JE, Shepherd A, **Wild A**, Imber B, Pei X, Gelb E, Travis W, Adusumilli P, Jones D, Isbell J, Chافت J, Wu A, Rimmer A. Tumor spread through airspaces and histologic subtype predict outcomes following post-operative radiotherapy for locally advanced lung adenocarcinoma. Oral presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.
3. **Wild A**, Fan KY, Dholakia AS, Ford E, Kumar R, Ye X, Tran PT, Grossman SA, Herman JM, Ellsworth SG. Stereotactic body radiation therapy results in less severe treatment-related lymphopenia than conventional chemoradiation therapy in patients with locally advanced pancreatic cancer. Oral presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
4. Dholakia AS, Kumar R, Raman SP, Yovino SG, **Wild AT**, Fan KY, Hacker-Prietz A, Tran PT, Wolfgang CL, Herman JM. Mapping Patterns of Local Failure Following Pancreaticoduodenectomy for Pancreatic Cancer: A New Approach to Adjuvant Radiation Fields. Oral presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
5. Dholakia AS, Kumar R, **Wild AT**, Fan KY, Hacker-Prietz A, Ellsworth S, Raman SP, Le DT, Laheru DA, De Jesus-Acosta A, Zheng L, Fishman E, Hruban RH, Weiss MJ, Pawlik TM, Cameron JL, Wolfgang CL, Herman JM. Patterns of local failure following pancreaticoduodenectomy for resectable pancreatic ductal adenocarcinoma. Oral presentation at the 46th Annual Meeting of the Pancreas Club, Orlando, FL, May 17-18, 2013.
6. Dholakia AS, Fan KY, **Wild AT**, Hacker-Prietz A, Le DT, De Jesus-Acosta A, Diaz LA, Laheru DA, Hruban RH, Fishman EK, Pawlik TM, Wolfgang CL, Herman JM. Hemoglobin-A1c as a predictor of clinical outcomes in patients seen in a pancreas multidisciplinary cancer clinic. Oral presentation at the American Radium Society 95th Annual Meeting, Scottsdale, AZ, April 27-May 1, 2013.
7. Fan KY, **Wild AT**, Hacker-Prietz A, Wood L, Blackford AL, Tran PT, Kumar R, Ellsworth S, Dholakia A, Zheng L, Le DT, De Jesus-Acosta A, Rasheed Z, Makary MA, Weiss MJ, Cameron JL, Pawlik TM, Laheru DA, Hruban RH, Fishman EK, Wolfgang CL, Herman JM. Treating pancreatic cancer patients with erlotinib based adjuvant therapy following pancreaticoduodenectomy or pancreatectomy. Oral presentation at the American Radium Society 95th Annual Meeting, Scottsdale, AZ, April 27-May 1, 2013.
8. Kumar R, Ziegler MA, **Wild AT**, Fan KY, Dholakia AS, Ellsworth S, Pawlik TM, Kamel IR, Herman JM, Geschwind JFH. Efficacy of radioembolization treatments with Yttrium-90 microspheres for liver metastases. Oral presentation at the American Brachytherapy Society 2013 Annual Meeting, New Orleans, LA, April 18-20, 2013.
9. Dholakia AS, Hacker-Prietz A, **Wild A**, Raman S, Laheru D, Zheng L, Le D, Pawlik T, Makary M, Wolfgang C, De Jesus-Acosta A, Herman J. Radiographic changes associated with surgical resection following neoadjuvant radiation therapy for locally advanced pancreatic adenocarcinoma. Oral presentation at the Americas Hepato-Pancreato-Biliary Association (AHPBA) 2013 Annual Meeting, Miami, FL, February 20-24, 2013.

10. **Wild AT**, Chang DT, Goodman KM, Laheru DA, Zheng L, Diaz LA, Le DT, Raman SP, Leal JP, Chaudhry MA, Sugar E, Columbo LA, Tom A, Limaye MR, Edil BH, Oteiza K, Hacker-Prietz A, Wolfgang CL, Koong A, Herman JM. A Phase II Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Oral presentation at ASTRO's Cancer Imaging and Radiation Therapy Symposium: A Multidisciplinary Approach, Orlando, FL, February 8-9, 2013. PMID: 24674559.
11. Ziegler MA, **Wild AT**, Pawlik TM, Laheru DA, Rajasen T, Wolfgang CL, Herman JM. Assessment of consistency in treatment recommendations among patients seen at a comprehensive pancreatic cancer multidisciplinary clinic. Oral presentation at the American College of Radiology Driving Value into Your Organization Through Quality and Safety Improvements Conference, Scottsdale, AZ, February 17-18, 2012.
12. **Wild AT**, Begly JP, Garzon-Muvdi J, Desai P, McFarland EG. Chest pain in a female lacrosse player. Oral presentation at the 57th Annual Meeting and Inaugural World Congress on Exercise is Medicine, Baltimore, MD, June 1-5, 2010.

POSTER PRESENTATIONS/PUBLISHED ABSTRACTS AT NATIONAL CONFERENCES:

[First Author]

1. **Wild AT**, Anderson E, Patel S, Samstein R, Xu A, Fatata A, Hurtado A, Kumar C, Lockney N, Martin K, Ostrovsky A, Stein D. Improving workflow efficiency and provider satisfaction in administration of radiation therapy to patients through implementation of a secure two-way text messaging system. Poster presentation at the 2017 AMIA Annual Symposium, Washington, D.C., November 3-8, 2017.
2. **Wild AT**, Kiess AP, Yang TJ, Weg ES, Kohutek ZA, Wolchok JD, Postow MA, Tabar V, Brennan CW, Chan TA, Yamada Y, Beal K. Improved survival and intracranial control associated with radiation necrosis after ipilimumab and stereotactic radiosurgery for melanoma brain metastases. Poster presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.
3. **Wild AT**, Shepherd A, Leeman JE, Imber BS, Pei X, Gelblum DY, Gelb E, Chaft JE, Jones DR, Isbell JM, Yorke ED, Wu AJ, Rimner A. FDG-PET maximum standardized uptake value is prognostic for survival and disease-free survival in stage IIIA-N2 non-small cell lung cancer patients who receive postoperative radiation therapy. Poster presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.
4. **Wild AT**, Jackson A, Kohutek ZA, Wu AJ, Gelblum DY, von Reibnitz D, Gelb E, Panchoo K, Yan M, Yorke ED, Rimner A. Planning target volume and FDG-PET maximum standardized uptake value, but not dosimetric parameters of target coverage, predict for local recurrence after stereotactic body radiation therapy for non-small cell lung cancer. Poster presentation at the 2016 ASTRO Annual Meeting, Boston, MA, September 26-28, 2016.
5. **Wild AT**, Dholakia AS, Fan KY, Kumar R, Laheru D, Diaz LA Jr., Zheng L, Le DT, De Jesus-Acost A, Ellsworth SG, Hacker-Prietz A, Voong KR, Weiss M, Hruban RH, Tran PT, Cameron JL, Pawlik TM, Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenocarcinoma of the pancreas. Poster presentation at the 2014 AGA-ASCO-ASTRO-SSO Gastrointestinal Cancers Symposium, San Francisco, CA, January 16-18, 2014.
6. **Wild A**, Bellovin D, Chettiar ST, Gandhi NG, Gajula RP, Williams RD, Cades JA, Walker A, Felsher D, Herman JM, Tran PT. Twist1 overexpression induces increased tumor cell aggressiveness and resistance to sorafenib in hepatocellular carcinoma cells. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
7. **Wild AT**, Dholakia AS, Fan KY, Kumar R, Laheru D, Diaz LA Jr., Zheng L, Le DT, De Jesus-Acost A, Ellsworth SG, Hacker-Prietz A, Voong KR, Weiss M, Hruban RH, Tran PT, Cameron JL, Pawlik TM,

- Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenocarcinoma of the pancreas. Published abstract at the 2013 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2013.
8. **Wild AT**, Hiniker SM, Chang DT, Tran PT, Khashab MA, Fan KY, Dholakia AS, Kumar R, Limaye MR, Laheru DA, Le DT, Pai JS, Hargens B, Sharabi AB, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: Experience from two institutions. Poster presentation at the 47th Annual Meeting of the Pancreas Club, Orlando, FL, May 17-18, 2013.
 9. **Wild AT**, Yovino S, Smith JA, Ziegler MA, Laheru DA, Zheng L, Balmanoukian AS, Tran PT, Pawlik TM, Wolfgang CL, Grossman SA, Herman JM. Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the NCI Frontiers in Basic Immunology Meeting, Bethesda, MD, October 4-5, 2012.
 10. **Wild AT**, Gandhi N, Aziz KA, Chettiar ST, Gajula RP, Kumar R, Torbenson MS, Hales RK, Herman JM, Tran PT. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma: A preclinical study. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
 11. **Wild AT**, Kim KJ, Tryggestad E, Roland T, Shin EJ, Tran PT, Kumar R, Wong J, Khashab MA, Herman JM. Utility of fiducials in image-guided SBRT for patients with locally advanced pancreatic cancer: Analysis of visibility and migration. Poster-discussion presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
 12. **Wild AT**, Hiniker SM, Limaye MR, Chang DT, Laheru DA, Tran PT, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. SBRT as a novel treatment option for locally recurrent pancreatic cancer after failure of definitive multimodality therapy: A multi-institutional case series. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
 13. **Wild AT**, Laheru DA, Wang H, Chang KF, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Davis YM, Klapman J, Reid T, Shah RJ, Wolfgang CL, Rosemurgy A, Herman JM. A randomized phase III multi-institutional study of TNFeradeTM biologic with 5-FU and radiotherapy for locally advanced pancreatic cancer: Final results. Poster presentation at the 2012 ASCO Annual Meeting, Chicago, IL, June 1-5.
 14. **Wild AT**, Yovino S, Ziegler MA, Ye X, Laheru DA, Zheng L, Tran PT, Hacker-Prietz A, Kumar R, Pawlik TM, Wolfgang CL, Grossman SA, Herman JM. Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the 2012 American College of Physicians (ACP) Steps to Success Meeting, Bethesda, MD, March 31.
 15. **Wild AT**, Balmanoukian AS, Laheru DA, Zheng L, Tran PT, Hacker-Prietz A, Yovino S, Kumar R, Ziegler MA, Pawlik TM, Wolfgang CL, Grossman SA, Herman JM. Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the 46th Annual Meeting of the Pancreas Club, San Diego, CA, March 2012.
 16. **Wild AT**, Kim K, Khashab MA, Shin EJ, Canto MI, Laheru DA, Ziegler MA, Tran PT, Pawlik TM, Wolfgang CL, Herman JM. Stereotactic body radiation therapy as a novel treatment option for locally recurrent pancreatic cancer after failure of definitive multimodality therapy. Poster presentation at the 46th Annual Meeting of the Pancreas Club, San Diego, CA, May 19-22, 2012.
 17. **Wild AT**, Yovino S, Smith JA, Ziegler MA, Laheru DA, Zheng L, Balmanoukian AS, Tran PT, Pawlik TM, Wolfgang CL, Grossman SA, Herman JM. Degree of chemoradiation-associated lymphopenia is related to

radiation field size in patients with locally advanced pancreatic cancer. Poster presentation at the 94th Annual Meeting of the American Radium Society, Las Vegas, NV, April 28-May 2, 2012.

18. **Wild AT**, Hacker-Prietz A, Daniel H, Maitra A, Torbenson MS, Pawlik TM, Geschwind JH, Herman JM, Tran PT. Radiosensitization of hepatocellular carcinoma using rationally combined molecular-targeted agents. Poster presentation at the 103rd AACR Annual Meeting, Chicago, IL, March 31-April 4, 2012.
19. **Wild AT**, Balmanoukian AS, Laheru DA, Zheng L, Tran PT, Hacker-Prietz A, Yovino S, Kumar R, Ziegler MA, Pawlik TM, Wolfgang CL, Grossman SA, Herman JM. Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the AGA-ASCO-ASTRO-SSO Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2012.
20. **Wild AT**, Marciscano AE, Hidalgo M, Laheru DA, Le D, Hacker-Prietz A, Ziegler MA, Edil BH, Tran PT, Zheng L, Pawlik TM, Schulick RD, Wolfgang CL, Herman JM. Preliminary results of a phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12-16, 2011.
21. **Wild AT**, Growing Spine Study Group, Sponseller PD. Growing rods for cerebral palsy. Poster presentation at the 4th International Congress on Early Onset Scoliosis and Growing Spine (ICEOS), Toronto, Ontario, Canada, November 19-20, 2010.
22. **Wild AT**, Growing Spine Study Group, Sponseller PD. Growing rods for cerebral palsy. Poster presentation at the 17th International Meeting on Advanced Spine Techniques (IMAST), Toronto, Canada, July 21-24, 2010.

[*Non-first Author*]

23. Shepherd A, **Wild A**, Gelblum D, Wu A, Rimner A. Patterns of care and outcomes of hypofractionated radiation therapy (HFRT) alone in patients with stage III non-small cell lung cancer (NSCLC). Submitted to the 2018 ASTRO Annual Meeting, San Antonio, TX, October 21-24, 2018.
24. Fontanella A, **Wild A**, Lim SB, Mechalakos JG, Popple RA, Fiveash JB, Yamada Y, Lovelock DM. A dosimetric analysis of dorsal nerve root ablation therapy using a virtual cone technique. Submitted to the 2018 ASTRO Annual Meeting, San Antonio, TX, October 21-24, 2018.
25. Lim S, LoSasso TJ, **Wild A**, Mechalakos J, Yamada Y, Lovelock D. The commissioning of AAA and AcurosXB with a 10MV flattening-filter-free beam for stereotactic radiosurgery. Submitted to the 2018 AAPM Annual Meeting, Nashville, TN, July 29 – August 2, 2018.
26. Lovelock D, Mostafavi H, Fontanella A, Lim S, **Wild A**, Yamada Y. Accuracy of template matching in the localization of a vertebral body during dose delivery. Submitted to the 2018 AAPM Annual Meeting, Nashville, TN, July 29 – August 2, 2018.
27. McKenney AS, Um HM, Yang TJ, Lin AL, Rosenblum M, Weg ES, **Wild AT**, Veeraraghavan H, Young R. Texture feature analysis of T1 MRI perfusion of pathology-proven pseudoprogression of glioblastoma. Submitted to the 2018 RSNA Annual Meeting, Chicago, IL, November 25-30, 2018.
28. Imber B, Leeman J, Shepherd A, **Wild A**, Pei X, Gelb E, Jones D, Isbell J, Chافت J, Wu A, Rimner A. Prognostic impact of tumor location and lymph node burden for patients with Stage IIIA non-small cell lung cancer receiving post-operative radiotherapy. Poster presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.

29. Shepherd A, Leeman J, **Wild A**, Imber B, Pei X, Gelb E, Yorke E, Jones D, Isbell J, Chaft J, Gelblum D, Wu A, Rimner A. A comparison of trimodality therapy vs. definitive concurrent chemoradiation in patients with stage IIIA non-small cell lung cancer. Poster presentation at the 2017 ASTRO Annual Meeting, San Diego, CA, September 25-27, 2017.
30. Elnahal SM, **Wild AT**, Dholakia AS, Fan KY, Huang P, Herman JM. Patient Factors that Predict Physician Room Time and Downstream Clinical Encounters in a Pancreatic Multidisciplinary Clinic. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
31. Chettiar ST, Gajula RP, Williams R, Gandhi N, Thijagarajan S, Aziz K, **Wild AT**, Kato Y, Herman JM, Hales RK, An S, Tran PT. Structure-function studies of the phosphorylated bHLH domain of the Twist1 oncoprotein for prostate cancer metastasis. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
32. Fan KY, **Wild AT**, Halappa VG, Kumar R, Ellsworth S, Pawlik TM, Cosgrove D, Kamel IR, Herman JM, Geschwind JF. Neuroendocrine Tumor Liver Metastases Treated with Yttrium-90 Radioembolization. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
33. Ellsworth S, Campian J, **Wild A**, Grossman S, Sarai G, Gearhart S, Azad N, Hacker-Prietz A, Shin EJ, Herman J. Sparing Circulating Lymphocyte Populations with Endorectal Brachytherapy. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
34. Pai J, Chiu W, Shultz D, Graber M, Columbo L, **Wild A**, Herman J, Chang D, Koong A. Plasma SPARC Following Stereotactic Body Radiotherapy (SBRT) Predicts for Progression-Free Survival in Locally Advanced Pancreatic Cancer. Poster presentation at the 2013 ASTRO Annual Meeting, Atlanta, GA, September 22-25, 2013.
35. Dholakia AS, Hacker-Prietz A, **Wild AT**, Raman SP, Wood LD, Laheru DA, Zheng L, De Jesus-Acosta A, Huang P, Le DT, Schulick RD, Edil BH, Ellsworth SG, Pawlik TM, Iacobuzio-Donahue CA, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer is not dependent on improved tumor-vessel relationships. Poster presentation at the 2013 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2013.
36. Fan KY, Dholakia AS, **Wild AT**, Su Z, Hacker-Prietz A, Kumar R, Hodgins M, Hsu CC, Le DT, De Jesus-Acosta A, Diaz LA Jr., Laheru DA, Hruban RH, Fishman EK, Brown TD, Pawlik TM, Wolfgang CL, Tran PT, Herman JM. Hemoglobin-A1c level predicts for clinical outcomes in patients with pancreatic cancer. Poster presentation at the 2013 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2013.
37. Herman JM, **Wild AT**, Dholakia AS, Fan KY, Laheru DA, Diaz Jr. LA, Zheng L, Le DT, Azad NS, Donehower R, Cosgrove D, Anders R, Cameron JL, Lutz E, Hruban RH, Edil BH, Schulick RD, Wolfgang CL. Pilot study evaluating an allogeneic GM-CSF-transduced pancreatic tumor cell vaccine (GVAX) and low dose cyclophosphamide integrated with fractionated stereotactic body radiation therapy (SBRT) and FOLFIRINOX chemotherapy in patients with resected adenocarcinoma of the pancreas. Poster presentation at the 47th Annual Meeting of the Pancreas Club, Orlando, FL, May 17-18, 2013.
38. Fan KY, **Wild AT**, Dholakia AS, Kumar R, Narang AK, Ellsworth S, Hacker-Prietz A, Hodgins M, Le DT, De Jesus-Acosta A, Laheru DA, Hruban RH, Ali S, Schulick RD, Zheng L, Fishman EK, Pawlik TM, Wolfgang CL, Herman JM. Impact of a single-day multidisciplinary clinic on the management of pancreatic cancer: 3-year update. Poster presentation at the 47th Annual Meeting of the Pancreas Club, Orlando, FL, May 17-18, 2013.
39. Dholakia AS, Leal J, **Wild AT**, Hacker-Prietz A, Chaudhry M, Diaz L, Wahl R, Laheru D, Wolfgang CL, Herman JM. Understanding the role of ¹⁸Fluorodeoxyglucose PET in predicting improved survival in locally advanced pancreatic cancer in a phase II trial utilizing gemcitabine and stereotactic radiotherapy. Poster

presentation at ASTRO's Cancer Imaging and Radiation Therapy Symposium: A Multidisciplinary Approach, Orlando, FL, February 8-9, 2013. PMID: 24674528.

40. Dholakia AS, Hacker-Prietz A, **Wild AT**, Raman SP, Wood LD, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, Rasheed Z, Yovino S, Fan K, Kumar R, Pawlik TM, Makary M, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma. Poster presentation at the American Radium Society 95th Annual Meeting, Scottsdale, AZ, April 27-May 1, 2013.
41. Grossman SA, Yovino S, Campian J, **Wild AT**, Herman JM, Laheru DA, Brock M, Marur S, Balmanoukian A, Ye X. The association between treatment-related lymphopenia and survival in patients with solid tumors. Poster presentation at the AACR 2013 Annual Meeting, Washington, DC, April 6-10, 2013.
42. Fan KY, Dholakia AS, **Wild AT**, Hacker-Prietz A, Le DT, De Jesus-Acosta A, Diaz LA, Laheru DA, Hruban RH, Fishman EK, Pawlik TM, Wolfgang CL, Herman JM. Hemoglobin-A1c as a predictor of clinical outcomes in patients seen in a pancreas multidisciplinary cancer clinic. Poster presentation at the AACR 2013 Annual Meeting, Washington, DC, April 6-10, 2013.
43. Kumar R, Dholakia AS, Smith JA, Leal JP, Chaudhry MA, **Wild AT**, Hacker-Prietz A, Raman SP, Hruban RH, Efron J, Wick EC, Azad NS, Diaz LA, Le Y, Armour E, Yovino SG, Herman JM, Gearhart S. First report of the correlation of perceist (PET Response Criteria in Solid Tumors) criteria and pathologic change in rectal cancer patients treated with neoadjuvant radiation. Poster presentation at the AGA/ASCO/ASTRO/SSO 2013 Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-27, 2013.
44. Fan K, **Wild AT**, Laheru DA, Pawlik TM, Zheng L, Le DT, Tran PT, Dholakia A, Kumar R, Yovino SG, Hacker-Prietz A, Rasheed Z, De Jesus-Acosta A, Weiss MJ, Makary MA, Cameron JL, Hruban RH, Fishman EK, Wolfgang CL, Herman JM. Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer. Poster presentation at the AGA/ASCO/ASTRO/SSO 2013 Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-27, 2013.
45. Dholakia AS, Hacker-Prietz A, **Wild AT**, Raman SP, Wood LD, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, Rasheed Z, Yovino SG, Kumar R, Fan KY, Pawlik TM, Makary M, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma. Poster presentation at the AGA/ASCO/ASTRO/SSO 2013 Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-27, 2013.
46. Dholakia AS, Moore JA, **Wild AT**, Yang W, Evans K, McNutt T, Herman JM. Feasibility and efficiency of automatic treatment planning for stereotactic body radiation therapy (SBRT) in pancreatic cancer patients. Poster presentation at the AGA/ASCO/ASTRO/SSO 2013 Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-27, 2013.
47. Elnahal SM, **Wild AT**, Wang H, Wolfgang CL, Pawlik TM, Herman JM. Preliminary decision-tree analysis of costs to payors associated with a pancreatic multidisciplinary clinic. Poster presentation at ASCO's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012.
48. Elnahal SM, **Wild AT**, Pawlik TM, Wang H, Gavney D, Snyder T, Biedrzycki BA, Jaffee EM, Langbaum T, Fishman EK, Hruban RH, Laheru DA, Hacker-Prietz A, Schulick RD, Makary M, Edil BH, Wolfgang CL, Herman JM. Patient retention and costs associated with a pancreatic multidisciplinary clinic. Poster presentation at ASCO's Quality Care Symposium, San Diego, CA, November 30-December 1, 2012.
49. Grossman SA, Yovino S, Campian J, **Wild AT**, Herman JM, Brock M, Ye X. Treatment-related immunosuppression: Observations in glioblastoma and other solid tumors. Poster presentation at the 17th

Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, DC, November 15-18, 2012.

50. Kumar R, Hobbs R, Hacker-Prietz A, Quon H, **Wild A**, Wang T, Armour E, Herman J. HDR brachytherapy provides rapid tumor response and low normal tissue toxicity in non-melanoma skin cancer of the face. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
51. Ziegler MA, Kumar R, **Wild AT**, Pawlik TM, Kamel IR, Herman JM, Geschwind JFH. Efficacy of radioembolization treatments with Yttrium-90 microspheres for hepatocellular carcinoma and liver metastases. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
52. Gandhi N, **Wild AT**, Aziz KA, Chettiar ST, Gajula RP, Zeng J, Herman JM, DeWeese TL, Hales RK, Tran PT. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Poster-discussion presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
53. Kumar R, **Wild AT**, Ziegler MA, Kang J, Smith KS, Tryggestad E, Ford E, Wong J, Hooker T, Herman J. SBRT treatment planning with VMAT versus IMRT: Impact of duodenal sparing on tumor coverage in patients with locally advanced pancreatic adenocarcinoma. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
54. Smith JA, **Wild AT**, Singhi A, Raman S, Kumar R, Kamel IR, Efron J, Azad N, Herman JM, Gearhart S. Clinicopathologic comparison of high dose rate endorectal brachytherapy and conventional chemoradiotherapy among patients with locally advanced low rectal cancer. Poster presentation at the 2012 ASTRO Annual Meeting, Boston, MA, October 28-31.
55. Herman JM, Chang DT, Goodman KM, **Wild AT**, Laheru DA, Zheng L, Diaz LA, Le DT, Raman SP, Leal JP, Chaudhry MA, Sugar E, Columbo LA, Tom A, Limaye MR, Edil BH, Oteiza K, Hacker-Prietz A, Wolfgang CL, Koong A. A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma. Poster presentation at the 2012 ASCO Annual Meeting, Chicago, IL, June 1-5.
56. Kumar R, Hobbs R, Hacker-Prietz A, Quon H, **Wild A**, Wang T, Armour E, Herman JM. HDR brachytherapy gives rapid tumor response and low normal tissue toxicity in non-melanoma skin cancer of the face. Poster presentation at the 2012 World Congress of Brachytherapy, Barcelona, Spain, May 10-12, 2012.
57. Kim K, Tryggestad E, **Wild AT**, Ziegler MA, Shin EJ, Canto MI, Herman JM, Khashab MA. Comparative analysis of traditional and visicoil fiducials implanted during endoscopic ultrasound for pancreatic cancer patients receiving stereotactic body radiation therapy. Poster presentation at the 2012 AASLD-AGA-AGSE-SSAT Digestive Disease Week, San Diego, CA, May 19-22, 2012.
58. Maidment BW, Ellison T, Herman JM, Sharma NK, Laheru DA, Regine WF, **Wild AT**, Olin K, Hruban RH, Cameron JL, Zheng L, Choti MR, Schulick RD, Wolfgang CL, Edil BH. Radiation in the management of pancreatic neuroendocrine tumors. Poster presentation at the AGA-ASCO-ASTRO-SSO Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2012.

REFERENCES:

Dr. Abraham J. Wu
Assistant Professor and Residency Program Director
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
1250 First Avenue, Mailbox 22
New York, NY 10065

(212) 639-5257
wua@mskcc.org

Dr. Suzanne Wolden
Professor
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
1250 First Avenue, Mailbox 22
New York, NY 10065
(212) 639-5148
woldens@mskcc.org

Dr. Christopher Barker
Assistant Professor
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
1250 First Avenue, Mailbox 22
New York, NY 10065
(212) 639-5257
barkerc@mskcc.org

Dr. Yoshiya (Josh) Yamada
Professor
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
1250 First Avenue, Mailbox 22
New York, NY 10065
(212) 639-2950
yamadaj@mskcc.org

Dr. Michael J. Zelefsky
Professor, Vice Chair, and Associate Residency Program Director
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
1250 First Avenue, Mailbox 22
New York, NY 10065
(212) 639-6802
zelefskm@mskcc.org